(Q46843916)

25 December 2017

title

Establishing pharmacokinetic bioequivalence of valganciclovir oral solution versus the tablet formulation (English)

1 reference

25 December 2017

1 reference

1 reference

M D Pescovitz

1

1 reference

25 December 2017

A Jain

2

1 reference

25 December 2017

R Robson

3

1 reference

25 December 2017

S Mulgaonkar

4

1 reference

25 December 2017

R Freeman

5

1 reference

25 December 2017

M R Bouw

6

1 reference

25 December 2017

language of work or name

English

0 references

publication date

1 December 2007

1 reference

25 December 2017

Transplantation Proceedings

published in

1 reference

25 December 2017

volume

39

1 reference

25 December 2017

issue

10

1 reference

25 December 2017

page(s)

3111-3116

1 reference

25 December 2017

Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.10.007

Management of cytomegalovirus infection and disease after solid-organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.10.007

Valganciclovir for the prophylaxis of cytomegalovirus disease in pediatric liver transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.10.007

Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.10.007

Prophylaxis of cytomegalovirus disease with intravenous ganciclovir in renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.10.007

Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.10.007

Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.10.007

Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.10.007

Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.10.007

Pharmacokinetics of valganciclovir and ganciclovir in renal impairment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.10.007

New AUC-based method to estimate drug fraction removed by hemodialysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.10.007

Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.10.007

Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.10.007

Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.10.007

10.1016/J.TRANSPROCEED.2007.10.007

7 January 2021

Identifiers

DOI

1 reference

25 December 2017

1 reference

25 December 2017